The place of quetiapine extended release in the treatmentof mental disorders;Miejsce kwetiapiny o przedłuzonym uwalnianiu w terapii osób z zaburzeniami psychicznymi

Psychiatria Polska

Volumn 49, Issue 1, 2015, Pages 67-80

  Styczen, Krzysztof ^a   Datka, Wojciech ^a   Jaeschke, Rafal ^a   Drozdowicz, Katarzyna ^a   Siwek, Marcin ^a   Dudek, Dominika ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bipolar disorder; Quetiapine XR; Schizophrenia

Indexed keywords

QUETIAPINE; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; DRUG EFFICACY; DRUG EXTENDED RELEASE; DRUG FORMULATION; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; QUALITY OF LIFE; SCHIZOPHRENIA; SLEEP DISORDER; ANXIETY DISORDERS; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; MENTAL DISORDERS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MENTAL DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84923822684     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/PP/33909     Document Type: Article

References (42)

1. Tyszkowska M, Podogrodzka M. Stygmatyzacja na drodze zdrowienia w chorobach psychicznych - czynniki bezposrednio zwiazane z leczeniem psychiatrycznym. Psychiatr. Pol. 2013; 47(6): 1011-1022.
2. Baldwin CM, Scott LJ. Quetiapine extended release: in schizophrenia. CNS Drugs 2009; 23(3): 261-269.
3. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M. i wsp. Interventions to improve safe and effective medicines use by consumers: An overview of systematic reviews. Cochrane Database Syst. Rev. 2014; 4: CD007768.
4. European Medicines Agency. Seroquel XR - Article 6(13) referral - Annex I, II, III, IV;2010. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Seroquel-XR-6/WC500099193.pdf[dostep: 06.10.2014].
5. Seroquel XR (opis substancji). Med. Prakt.; http://indeks.mp.pl/desc.php?id=7652 [dostep: 06.10.2014].
6. Peuskens J, Trivedi J, Malyarov S, Brecher M, Svensson O, Miller F. i wsp. Prevention of schizo-phrenia relapse with extended release quetiapine fumarate dosed once daily: A randomized, placebo-controlled trial in clinically stable patients. Psychiatry 2007; 4(11): 34-50.
7. Moller HJ, Johnson S, Mateva T, Brecher M, Svensson O, Miller F. i wsp. Evaluation of the fea-sibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int. Clin. Psychopharmacol. 2008; 23(2): 95-105.
8. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O. i wsp. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007; 68(6): 832-842.
9. Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol. Bull. 2008; 41(3): 11-35.
10. Peuskens J, Trivedi JK, Brecher M, Miller F, Study I. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. Int. Clin. Psychopharmacol. 2010; 25(3): 183-187.
11. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr. Res. 2013; 147(1): 95-102.
12. Naber D, Peuskens J, Schwarzmann N, Goltz M, Kruger H, Lambert M. i wsp. Subjective well-being in schizophrenia: A randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). Eur. Neuropsychopharmacol. 2013; 23(10): 1257-1269.
13. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- And active-controlled study followed by a 6-month double-blind extension. Eur. Neuropsychopharmacol. 2013; 23(11): 1373-1382.
14. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH. i wsp. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- And active-controlled trial. Schizophr. Res. 2013; 145(1-3): 101-109.
15. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D. i wsp. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizo-phrenia. Curr. Med. Res. Opin. 2008; 24(1): 21-32.
16. Malhi GS, Bargh DM, McIntyre R, Gitlin M, Frye MA, Bauer M. i wsp. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord. 2012; 14(supl. 2): 1-21.
17. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M. i wsp. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15(1): 1-44.
18. Rybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 2013; 27(3): 165-173.
19. Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: A multicenter, randomized, double-blind, phase IV study. Clin. Ther. 2012; 34(11): 2202-2211.
20. Cristancho MA, Thase ME. The role of quetiapine extended release in the treatment of bipolar depression. Adv. Ther. 2010; 27(11): 774-784.
21. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog. Neuropsychop-harmacol. Biol. Psychiatry 2009; 33(2): 199-204.
22. Kim SJ, Lee YJ, Lee YJ, Cho SJ. Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression. J. Affect. Disord. 2014; 157: 33-40.
23. Sanford M, Keating GM. Quetiapine: A review of its use in the management of bipolar depres-sion. CNS Drugs 2012; 26(5): 435-460.
24. Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetia-pine as monotherapy for the treatment of adults with acute mania: A randomized, double-blind, 3-week trial. Clin. Ther. 2011; 33(11): 1643-1658.
25. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J. Affect. Disord. 2010; 121(1-2): 106-115.
26. Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D. i wsp. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J. Affect. Disord. 2013; 145(1): 83-94.
27. Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C. i wsp. Efficacy and safety of quetiapine- XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: A randomized, placebo-controlled trial. J. Clin. Psychiatry 2014; 75(10): 1062-1068.
28. Pompili M, Rihmer Z, Gonda X, Serafini G, Sher L, Girardi P. Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: The role of quetiapine XR in the treatment of unipolar and bipolar depression. Riv. Psichiatr. 2012; 47(6): 489-497.
29. Earley W, McIntyre A, Wang G, Raines S, Ericsson HA. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Int. J. Psychiatry Clin. Pract. 2008; 12(supl. 4): 332.
30. Katila H, Mezhebowsky I, Mulroy A, Berggren L, Datto C, Erikson HA. i wsp. Efficacy and tol-erability of once-daily extended release quetiapine-fumarate (quetiapine XR) monotherapy inelderly patients wih major depressive disorder (MDD). Int. J. Psychiatry Clin. Pract. 2008; 18(supl. 4): 337.
31. Sanford M. Quetiapine extended release: Adjunctive treatment in major depressive disorder. CNS Drugs 2011; 25(9): 803-813.
32. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: A meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry 2012; 12: 160.
33. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. i wsp. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14(supl. 1): S1.
34. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: A randomized, placebo controlled and active-controlled study. Int. Clin. Psychopharmacol. 2012; 27(1): 40-54.
35. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: A long-term, randomized, placebo-controlled trial. Int. Clin. Psychopharmacol. 2011; 26(1): 11-24.
36. Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: A randomized, double-blind study. Ann. Clin. Psychiatry 2013; 25(4): E7-E22.
37. Endicott J, Svedsater H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr. Dis. Treat. 2012; 8: 301-311.
38. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst. Rev. 2010(12): CD008120.
39. LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: A systematic review and meta-analysis. J. Clin. Psychopharmacol. 2011; 31(3): 326-333.
40. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S. i wsp. Extended-release qu-etiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- And active-controlled study. Int. J. Neuropsychopharmacol. 2010; 13(3): 305-320.
41. Górna K, Jaracz K, Jaracz J, Kiejda J, Grabowska-Fudala B, Rybakowski J. Funkcjonowanie społeczne i jakosć zycia u chorych na schizofrenie - zaleznosć z remisja objawowa i czasem trwania choroby. Psychiatr. Pol. 2014; 48(2): 277-288.
42. Tyszkowska M, Jarema M. Miedzy zdrowiem a schizofrenia. Psychiatr. Pol. 2013; 47(4): 587-597.